Former Duke University professor and Sphinx Pharmaceuticals founder Robert Bell, PhD, named VP-research of Glaxo, Inc. Bell, a biochemist, will direct discovery research in cancer and metabolic disease as well as development of "products in all therapeutic areas." He replaces Leslie Hudson, PhD, who is now chief operating officer of Repligen. Senior VP/Director of the Glaxo Research Institute James Niedel, MD/PhD, will become group R&D director and managing director of Glaxo R&D in the U.K.; Niedel will be replaced by Terence Eaves, PhD, formerly development director of Glaxo R&D. James Palmer, MD, currently senior VP of Glaxo, Inc., will become Glaxo group development director
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: